AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses In

1. AbbVie’s Telisotuzumab Vedotin (Teliso-V) Demonstrated Encouraging Responses In C-MET NSCLC Patients Who Progressed on Previous Treatments

2. Phase II study of telisotuzumab vedotin in patients with c–MET+ NSCLC who have previously received not more than 2 lines prior systemic therapy (Abstract # 9016) An anti-c-MET antibody-drug conjugate (ADC) called telisotuzumab vedotin is made up of a monoclonal antibody attached to monomethyl auristatin E. (MMAE). In the Phase I Study (MN14-237), Teliso-V and osimertinib are given to patients with previously treated NSCLC who have c-MET overexpression. Recently, the FDA granted the medication Breakthrough Therapy Designation (BTD) for use as monotherapy in patients with metastatic or advanced EGFR-wt non-squamous NSCLC whose cancer has progressed or grown after receiving platinum-based therapy. Results of patients treated with Teliso-V and osimertinib in Phase I/Ib who had EGFR L858R, ex 19 deletions, and overexpression of c-MET. An ORR of 58 percent was seen when Teliso-V and osimertinib were combined. According to its recommended dosage, Teliso-V had an ORR of 3 (43%) out of 7 patients receiving 1.6 mg/kg and 8 (67%) out of 12 patients receiving 1.9 mg/kg. A preliminary analysis from the Phase II LUMINOSITY trial, which involved 136 patients and of whom 122 could be evaluated for the main outcome, was given by AbbVie. The objective response rate (ORR) as determined by an impartial central review served as the primary endpoint. The Bayesian model predicts that stage 2 advancement is more likely if at least 70% of the genuine ORR is present. 131 (96%) of patients experienced treatment-emergent adverse events (TEAEs) of any grade, and 65 patients experienced Grade 3+ adverse events (48 percent of patients). KOL insights “Patients with NSCLC have a high unmet need, and telisotuzumab vedotin has the potential to provide them with an additional treatment option to manage their disease.”–Expert Opinion. Conclusion The effectiveness of both cytotoxic chemotherapy and targeted therapy is affected by the anti-cancer treatment class known as antibody-drug conjugates (ADCs), which can deliver cytotoxic medications directly to tumour cells. The use of ADCs is expanding quickly, and early research in lung cancer has produced

3. encouraging results. ADCs that target HER2, HER3, TROP2, CEACAM5, and MET are now being tested in clinical studies for NSCLC. Oncogene tyrosine kinase receptor (c-MET) is the term used to describe this substance. Numerous cellular processes can be regulated by c-MET, and when these processes are dysregulated, tumour cells are more likely to proliferate, survive, invade, and spread. Point mutations, amplification, fusion, and protein overexpression are c-MET changes found in NSCLC that are linked to a poor prognosis. MET activation has previously been implicated as both a primary oncogenic driver mutation and a secondary driver of acquired resistance to targeted therapy in other genomic subpopulations, according to preclinical and clinical investigations. Agents that target c-MET are thus a possible therapeutic approach for NSCLC. There isn't currently a targeted medication that specifically targets NSCLC with c- MET overexpression. Therefore, obtaining a BTD can be essential in securing approval for the primary therapy in this patient group by providing this chemical. Companies- Janssen, Cullinan Oncology, Immutep, Bristol Myers Squibb, Merck Sharp & Dohme, Surface Oncology, AbbVie, Daiichi Sankyo, Chugai Pharmaceutical, Regeneron, Sanofi, and others. Get in touch with our Business Expert @Business Consulting Services | Biotech Consulting | Technical Due Diligence Firms About ASCO 2022 Conference Updates asco 2021 highlights | asco highlights 2021 | asco medical conference | asco 2021 | asco 2021 conference | when is asco 2021 | 2021 asco | 2021 asco annual meeting | asco convention | asco conference 2021 | asco 2021 | asco 21 | asco us | asco 2022 annual meeting | asco abstract 2022